Trials / Withdrawn
WithdrawnNCT00781794
Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients
A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of Single Oral Doses of NSA-789 on Auditory P50 Suppression in Nonsmoking Patients With Stabilized Schizophrenia
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of single doses of NSA-789 on the P50 component of the auditory evoked potentials and to assess the safety, tolerability and the concentration of NSA-789 in the blood, in nonsmoking patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NSA-789 at 2 different doses |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2008-10-29
- Last updated
- 2021-08-20
Locations
3 sites across 2 countries: United States, France
Source: ClinicalTrials.gov record NCT00781794. Inclusion in this directory is not an endorsement.